| Dr Gerald Sundt Davis, MD | |
|
111 Colchester Ave, Fletcher Allen Health Care - Acc East Pav 5, Burlington, VT 05401-1473 | |
| (802) 847-1158 | |
| Not Available |
| Full Name | Dr Gerald Sundt Davis |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Pulmonary Disease |
| Location | 111 Colchester Ave, Burlington, Vermont |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1659488039 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | (Vermont) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Gerald Sundt Davis, MD 4367 St George Rd, Williston, VT 05495-7687 Ph: (802) 878-2109 | Dr Gerald Sundt Davis, MD 111 Colchester Ave, Fletcher Allen Health Care - Acc East Pav 5, Burlington, VT 05401-1473 Ph: (802) 847-1158 |
News Archive
Lethal injection is the most common way people are legally put to death in the USA. It has eclipsed all other methods of execution because of public perception that the process is relatively humane and does not violate the US Constitution's Eight Amendment prohibiting cruel and unusual punishment.
Mergers between Catholic and secular hospitals could mean wider restriction of abortion, even as lawmakers in many states consider tighter regulation or bans on the procedure.
CVD (cardiovascular diseases) are proven to be the leading cause of deaths throughout the world. If statistics are reviewed, almost four out of five deaths are due to myocardial infarction or stroke.
Since 2016, a federal regulation has allowed nurse practitioners and physician assistants to obtain a waiver to prescribe buprenorphine, a medication used to treat opioid use disorder as a medication assisted treatment.
Eisai Europe Ltd. today announced that it has submitted a marketing authorization application to the European Medicines Agency (EMA) for approval of eribulin mesylate, also known as 'E7389', for the treatment of locally advanced or metastatic breast cancer in Europe. Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai. Regulatory applications for eribulin mesylate have also been submitted in the United States and Japan.
› Verified 3 days ago
Nadia Ghallab, Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 111 Colchester Ave, Burlington, VT 05401 Phone: 802-847-0000 | |
Beach Conger, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 617 Riverside Ave, Burlington, VT 05401 Phone: 802-864-6309 Fax: 802-860-4313 | |
Dr. Christopher Dwight Huston, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 111 Colchester Ave, Burlington, VT 05401 Phone: 802-847-2264 | |
Beth Diane Kirkpatrick, M.D. Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 111 Colchester Ave, Fletcher Allen Health Care, Burlington, VT 05401 Phone: 802-847-4594 | |
Dr. Richard Frank Branda, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 1 S. Prospect St, Burlington, VT 05401 Phone: 802-847-3827 Fax: 802-847-3510 | |
Lauren Suggs, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 111 Colchester Ave, Burlington, VT 05401 Phone: 802-847-0000 | |
Magdalena Anna Zeglin, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 111 Colchester Ave, Burlington, VT 05401 Phone: 802-847-0000 |